Today: 21 July 2026
Browse Category

Pharmaceuticals 17 November 2025 - 23 November 2025

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer Inc. heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the past few days the pharma giant has closed a multibillion‑dollar obesity acquisition, secured a major new U.S. cancer approval, sold $6 billion in new bonds and agreed to a $41.5 million legal settlement in Texas – while new analysis published today highlights both its long‑term potential and its risks. Reuters+3Pfizer+3Pfizer+3
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer stock heads into the weekend trading just above $25, with investors digesting a busy week of news: a strong Q3 earnings beat, a fresh FDA cancer-drug approval, completion of a multi‑billion‑dollar obesity deal, a new $6 billion bond issue – and even a headline‑grabbing bird flu case that once again reminds markets of Pfizer’s role in vaccines and antivirals. Benzinga+3Business Wire+3Pfizer+3
23 November 2025
···
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

As of late morning in New York, Novo Nordisk’s U.S. ADR is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion. In Copenhagen, Novo Nordisk’s B‑shares finished the session around DKK 305, down nearly 3% and extending a steep slide that has left the stock down about 45% year‑to‑date. Investing.com+1
21 November 2025
···
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

KVUE softened today after Monday’s developments in federal litigation tied to claims that prenatal acetaminophen use raises autism risk. A three‑judge appeals panel questioned the lower court’s dismissal of those cases, opening the door to their potential return and keeping headline risk front‑and‑center for the stock. Reuters
18 November 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Summary: Novo Nordisk remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its ConvaTec stake in London. U.S.-listed shares were modestly lower intraday as investors weighed near‑term pricing pressure against potential volume gains and ongoing governance/pipeline developments. Reuters+2NovoCare+2
18 November 2025
··
1 … 36 37 38 39 40 … 44
Go toTop